Literature DB >> 27338215

Role of Intraoperative Neurophysiologic Monitoring in the Resection of Thalamic Astrocytomas.

Giorgio Carrabba1, Giulio Bertani2, Filippo Cogiamanian3, Gianluca Ardolino3, Barbara Zarino2, Andrea Di Cristofori4, Marco Locatelli2, Manuela Caroli2, Paolo Rampini2.   

Abstract

BACKGROUND: The thalamus is a deep-seated and crucial structure for the sensorimotor system. It has been long considered a surgically inaccessible area because of the morbidity associated with surgical resections. Astrocytomas of the thalamus are usually treated with bioptic procedures followed by adjuvant treatments. Intraoperative neurophysiologic monitoring (IONM) allows safe and satisfactory resections of lobar gliomas, but few data are available for thalamic lesions. The aim of this study was to review the outcome of a small series of patients with thalamic astrocytomas that were treated with surgical resection with the aid of IONM.
METHODS: Surgical resection with IONM was performed in 5 patients with thalamic astrocytomas (1 grade I, 1 grade II, 2 grade III, 1 grade IV). Two astrocytomas were in the dominant hemisphere. Preoperative and postoperative neuropsychological assessments were performed in 3 patients. IONM was tailored to the individual patient and consisted of transcranial motor evoked potential monitoring, cortical motor evoked potential monitoring, somatosensory evoked potential monitoring, direct electrical stimulation, electroencephalography, and electrocorticography.
RESULTS: None of the patients experienced permanent motor deficits; 2 patients had a transient hemiparesis requiring rehabilitation; 1 patient had a transient aphasia, and 1 patient had permanent aphasia. None of the patients had intraoperative seizures, but 1 patient experienced postoperative transient status epilepticus. The extent of resection on postoperative volumetric magnetic resonance imaging was >70% in all cases.
CONCLUSIONS: Surgical resection of thalamic astrocytomas appeared to be effective and relatively safe when guided by IONM. Larger series of patients are required to confirm these preliminary data.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain mapping; Glioma surgery; Gliomas; Neurophysiologic monitoring; Thalamic glioma; Thalamus

Mesh:

Year:  2016        PMID: 27338215     DOI: 10.1016/j.wneu.2016.06.049

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Distant recurrences limit the survival of patients with thalamic high-grade gliomas after successful resection.

Authors:  Ryuta Saito; Toshihiro Kumabe; Masayuki Kanamori; Yukihiko Sonoda; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2016-12-17       Impact factor: 3.042

2.  Insular lobe surgery and cognitive impairment in gliomas operated with intraoperative neurophysiological monitoring.

Authors:  Barbara Zarino; Martina Andrea Sirtori; Tommaso Meschini; Giulio Andrea Bertani; Manuela Caroli; Cristina Bana; Linda Borellini; Marco Locatelli; Giorgio Carrabba
Journal:  Acta Neurochir (Wien)       Date:  2020-11-24       Impact factor: 2.216

3.  Surgical and molecular considerations in the treatment of pediatric thalamopeduncular tumors.

Authors:  Ryan P Lee; Kimberly A Foster; Jock C Lillard; Paul Klimo; David W Ellison; Brent Orr; Frederick A Boop
Journal:  J Neurosurg Pediatr       Date:  2017-07-07       Impact factor: 2.375

4.  Risk Factors for Early Hydrocephalus on Post Unilateral Thalamic Tumor Resection.

Authors:  Linpeng Zhang; Chen Wang; Xianwei Zeng
Journal:  Front Surg       Date:  2022-04-08

5.  Diffusion tensor imaging, intra-operative neurophysiological monitoring and small craniotomy: Results in a consecutive series of 103 gliomas.

Authors:  Giorgio Carrabba; Giorgio Fiore; Andrea Di Cristofori; Cristina Bana; Linda Borellini; Barbara Zarino; Giorgio Conte; Fabio Triulzi; Alessandra Rocca; Carlo Giussani; Manuela Caroli; Marco Locatelli; Giulio Bertani
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.